


Lofexidine

Cat. No.:	HY-B1052A	
CAS No.:	31036-80-3	
Molecular Formula:	C ₁₁ H ₁₂ Cl ₂ N ₂ O	
Molecular Weight:	259.13	
Target:	Adrenergic Receptor	
Pathway:	GPCR/G Protein; Neuronal Signaling	
Storage:	Powder	-20°C 3 years 4°C 2 years
	In solvent	-80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 62.5 mg/mL (241.19 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	3.8591 mL	19.2953 mL	38.5907 mL
		5 mM	0.7718 mL	3.8591 mL	7.7181 mL
10 mM		0.3859 mL	1.9295 mL	3.8591 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (8.03 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (8.03 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (8.03 mM); Clear solution 				

BIOLOGICAL ACTIVITY

Description	Lofexidine is a selective α ₂ -receptor agonist, commonly used to alleviate the physical symptoms of heroin and other types of opioid withdrawal ^{[1][2]} .
IC₅₀ & Target	α ₂ -receptor ^{[1][2]} .

REFERENCES

[1]. Vartak AP, et al. The preclinical discovery of lofexidine for the treatment of opiate addiction. *Expert Opin Drug Discov.* 2014 Nov;9(11):1371-7.

[2]. Gish EC, et al. Lofexidine, an α_2 -receptor agonist for opioid detoxification. *Ann Pharmacother.* 2010 Feb;44(2):343-51.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA